# L218CAR19 in Patients With Relapsed/Refractory B-cell Lymphoma

> **NCT06478381** · PHASE1 · RECRUITING · sponsor: **Henan Cancer Hospital** · enrollment: 22 (estimated)

## Conditions studied

- Relapsed/Refractory B-cell Lymphomas

## Interventions

- **DRUG:** L218CAR19

## Key facts

- **NCT ID:** NCT06478381
- **Lead sponsor:** Henan Cancer Hospital
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-06-01
- **Primary completion:** 2025-12-31
- **Final completion:** 2026-06-30
- **Target enrollment:** 22 (ESTIMATED)
- **Last updated:** 2024-06-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06478381

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06478381, "L218CAR19 in Patients With Relapsed/Refractory B-cell Lymphoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06478381. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*